All-trans retinoic acid and arsenic combination therapy benefits low-to-intermediate-risk patients with newly diagnosed acute promyelocytic leukaemia: a long-term follow-up based on multivariate analysis.
All-trans retinoic acid and arsenic combination therapy benefits low-to-intermediate-risk patients with newly diagnosed acute promyelocytic leukaemia: a long-term follow-up based on multivariate analysis.
复制标题
DOI：
--
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
Chen, Zhu;Wang, Zhenyi;Li, Junmin;Chen, Saijuan;
